A Mycobacterium tuberculosis-specific subunit vaccine that provides synergistic immunity upon co-administration with Bacillus Calmette-Guérin

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

A Mycobacterium tuberculosis-specific subunit vaccine that provides synergistic immunity upon co-administration with Bacillus Calmette-Guérin. / Woodworth, Joshua S.; Clemmensen, Helena Strand; Battey, Hannah; Dijkman, Karin; Lindenstrøm, Thomas; Laureano, Raquel Salvador; Taplitz, Randy; Morgan, Jeffrey; Aagaard, Claus; Rosenkrands, Ida; Lindestam Arlehamn, Cecilia S.; Andersen, Peter; Mortensen, Rasmus.

In: Nature Communications, Vol. 12, 6658, 2021.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Woodworth, JS, Clemmensen, HS, Battey, H, Dijkman, K, Lindenstrøm, T, Laureano, RS, Taplitz, R, Morgan, J, Aagaard, C, Rosenkrands, I, Lindestam Arlehamn, CS, Andersen, P & Mortensen, R 2021, 'A Mycobacterium tuberculosis-specific subunit vaccine that provides synergistic immunity upon co-administration with Bacillus Calmette-Guérin', Nature Communications, vol. 12, 6658. https://doi.org/10.1038/s41467-021-26934-0

APA

Woodworth, J. S., Clemmensen, H. S., Battey, H., Dijkman, K., Lindenstrøm, T., Laureano, R. S., Taplitz, R., Morgan, J., Aagaard, C., Rosenkrands, I., Lindestam Arlehamn, C. S., Andersen, P., & Mortensen, R. (2021). A Mycobacterium tuberculosis-specific subunit vaccine that provides synergistic immunity upon co-administration with Bacillus Calmette-Guérin. Nature Communications, 12, [6658]. https://doi.org/10.1038/s41467-021-26934-0

Vancouver

Woodworth JS, Clemmensen HS, Battey H, Dijkman K, Lindenstrøm T, Laureano RS et al. A Mycobacterium tuberculosis-specific subunit vaccine that provides synergistic immunity upon co-administration with Bacillus Calmette-Guérin. Nature Communications. 2021;12. 6658. https://doi.org/10.1038/s41467-021-26934-0

Author

Woodworth, Joshua S. ; Clemmensen, Helena Strand ; Battey, Hannah ; Dijkman, Karin ; Lindenstrøm, Thomas ; Laureano, Raquel Salvador ; Taplitz, Randy ; Morgan, Jeffrey ; Aagaard, Claus ; Rosenkrands, Ida ; Lindestam Arlehamn, Cecilia S. ; Andersen, Peter ; Mortensen, Rasmus. / A Mycobacterium tuberculosis-specific subunit vaccine that provides synergistic immunity upon co-administration with Bacillus Calmette-Guérin. In: Nature Communications. 2021 ; Vol. 12.

Bibtex

@article{7fbcc7b95aa446629b5c9df4db0c9deb,

title = "A Mycobacterium tuberculosis-specific subunit vaccine that provides synergistic immunity upon co-administration with Bacillus Calmette-Gu{\'e}rin",

abstract = "Given the encouraging clinical results of both candidate subunit vaccines and revaccination with Bacillus Calmette-Gu{\'e}rin (BCG) against tuberculosis (TB), there is support for combining BCG and subunit vaccination for increased efficacy. BCG and Mycobacterium tuberculosis (Mtb) share ~98% of their genome and current subunit vaccines are almost exclusively designed as BCG boosters. The goal of this study is to design a TB subunit vaccine composed of antigens not shared with BCG and explore the advantages of this design in a BCG + subunit co-administration vaccine strategy. Eight protective antigens are selected to create an Mtb-specific subunit vaccine, named H107. Whereas traditional vaccines containing BCG-shared antigens exhibit in vivo cross-reactivity to BCG, H107 shows no cross-reactivity and does not inhibit BCG colonization. Instead, co-administering H107 with BCG leads to increased adaptive responses against both H107 and BCG. Importantly, rather than expanding BCG-primed T cells, H107 broadens the overall vaccine repertoire with new T cell clones and introduces {\textquoteleft}adjuvant-imprinted{\textquoteright} qualities including Th17 responses and less-differentiated Th1 cells. Collectively, these features of H107 are associated with a substantial increase in long-term protection.",

author = "Woodworth, {Joshua S.} and Clemmensen, {Helena Strand} and Hannah Battey and Karin Dijkman and Thomas Lindenstr{\o}m and Laureano, {Raquel Salvador} and Randy Taplitz and Jeffrey Morgan and Claus Aagaard and Ida Rosenkrands and {Lindestam Arlehamn}, {Cecilia S.} and Peter Andersen and Rasmus Mortensen",

note = "Publisher Copyright: {\textcopyright} 2021, The Author(s).",

year = "2021",

doi = "10.1038/s41467-021-26934-0",

language = "English",

volume = "12",

journal = "Nature Communications",

issn = "2041-1723",

publisher = "nature publishing group",

}

RIS

TY - JOUR

T1 - A Mycobacterium tuberculosis-specific subunit vaccine that provides synergistic immunity upon co-administration with Bacillus Calmette-Guérin

AU - Woodworth, Joshua S.

AU - Clemmensen, Helena Strand

AU - Battey, Hannah

AU - Dijkman, Karin

AU - Lindenstrøm, Thomas

AU - Laureano, Raquel Salvador

AU - Taplitz, Randy

AU - Morgan, Jeffrey

AU - Aagaard, Claus

AU - Rosenkrands, Ida

AU - Lindestam Arlehamn, Cecilia S.

AU - Andersen, Peter

AU - Mortensen, Rasmus

PY - 2021

Y1 - 2021

N2 - Given the encouraging clinical results of both candidate subunit vaccines and revaccination with Bacillus Calmette-Guérin (BCG) against tuberculosis (TB), there is support for combining BCG and subunit vaccination for increased efficacy. BCG and Mycobacterium tuberculosis (Mtb) share ~98% of their genome and current subunit vaccines are almost exclusively designed as BCG boosters. The goal of this study is to design a TB subunit vaccine composed of antigens not shared with BCG and explore the advantages of this design in a BCG + subunit co-administration vaccine strategy. Eight protective antigens are selected to create an Mtb-specific subunit vaccine, named H107. Whereas traditional vaccines containing BCG-shared antigens exhibit in vivo cross-reactivity to BCG, H107 shows no cross-reactivity and does not inhibit BCG colonization. Instead, co-administering H107 with BCG leads to increased adaptive responses against both H107 and BCG. Importantly, rather than expanding BCG-primed T cells, H107 broadens the overall vaccine repertoire with new T cell clones and introduces ‘adjuvant-imprinted’ qualities including Th17 responses and less-differentiated Th1 cells. Collectively, these features of H107 are associated with a substantial increase in long-term protection.

AB - Given the encouraging clinical results of both candidate subunit vaccines and revaccination with Bacillus Calmette-Guérin (BCG) against tuberculosis (TB), there is support for combining BCG and subunit vaccination for increased efficacy. BCG and Mycobacterium tuberculosis (Mtb) share ~98% of their genome and current subunit vaccines are almost exclusively designed as BCG boosters. The goal of this study is to design a TB subunit vaccine composed of antigens not shared with BCG and explore the advantages of this design in a BCG + subunit co-administration vaccine strategy. Eight protective antigens are selected to create an Mtb-specific subunit vaccine, named H107. Whereas traditional vaccines containing BCG-shared antigens exhibit in vivo cross-reactivity to BCG, H107 shows no cross-reactivity and does not inhibit BCG colonization. Instead, co-administering H107 with BCG leads to increased adaptive responses against both H107 and BCG. Importantly, rather than expanding BCG-primed T cells, H107 broadens the overall vaccine repertoire with new T cell clones and introduces ‘adjuvant-imprinted’ qualities including Th17 responses and less-differentiated Th1 cells. Collectively, these features of H107 are associated with a substantial increase in long-term protection.

U2 - 10.1038/s41467-021-26934-0

DO - 10.1038/s41467-021-26934-0

M3 - Journal article

C2 - 34795205

AN - SCOPUS:85119417065

VL - 12

JO - Nature Communications

JF - Nature Communications

SN - 2041-1723

M1 - 6658

ER -

ID: 285798316

Forskning